Navigation Links
Merck Serono Named as a Top Employer by Science Magazine
Date:10/9/2008

GENEVA, Switzerland, October 10 /PRNewswire-FirstCall/ --

- Ranked Number 7 out of top 20 Employers Across Life Sciences Industry

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has been named by Science magazine as a top employer in the biotechnology and pharmaceutical industries, ranking number 7 out of the top 20 employers across the life sciences.

"We are honored that the scientific community has recognized Merck Serono as a leading place to work," said Bernhard Kirschbaum, Executive Vice President, Research, Merck Serono. "Our success as a leader within the biopharmaceutical industry is a direct result of the hard work, passion and dedication of our employees. We are committed to creating an environment for our scientists that fosters growth, professional development and a place where intellectually curious people can thrive and grow with a common goal of finding new treatments for unmet medical needs."

This is the second time Merck Serono has been placed on Science magazine's Top Employer survey; previously the organization ranked number 17.

The survey sought to determine which biotechnology and pharmaceutical companies were most admired by people who work in the field, and why. Survey respondents also rated the companies on 23 different attributes, which included Corporate Image, Financial Prowess, Leadership and Direction, Work/Culture Environment, Location and Academic and Intellectual Challenge. The methodology used for the survey included email invitations to AAAS members, Science Careers registrants, and Science website visitors.

The ranking is a result of a survey conducted by Science magazine, along with the American Association for the Advancement of Science (AAAS), and commissioned by Senn-Delaney Culture Diagnostics and Measurement to conduct a web-based survey aimed at determining the companies in the biotechnology and pharmaceutical industries with the best reputations as employers.

About Merck Serono

Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. Its North American business operates in the United States and Canada as EMD Serono.

Merck Serono has leading brands serving patients with cancer (Erbitux(R)), multiple sclerosis (Rebif(R)), infertility (Gonal-f(R)), endocrine and cardiometabolic disorders (Glucophage(R), Concor(R), Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)).

With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.

About Merck

Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.1 billion in 2007, a history that began in 1668, and a future shaped by 31,946 employees in 60 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit http://www.merckserono.net or http://www.merck.de


'/>"/>
SOURCE Merck Serono
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
2. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
3. BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance
4. New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting
5. Merck & Co., Inc. Named Keynote Sponsor For Diversity Alliance For Sciences Inaugural Conference
6. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
9. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
10. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
11. EMD Serono Named as a Top Employer by Science Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... South Jordan, UT, and Portland, OR (PRWEB) , ... ... ... CallTower , an industry-leading Unified Communications (UC) and Collaboration ... cloud performance in real-time, announced today a strategic alliance to extend CallTower’s ...
(Date:9/25/2017)... ... 25, 2017 , ... Having met specific requirements for its ... found to provide product development services that consistently meet customer and ... have a lot at stake when they invest in developing medical ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... studies, presentations and demonstrations at SCDM 2017, held September 24-27, 2017 in ... teams and CRO partners for more automated capabilities across evolving data, Comprehend ...
(Date:9/22/2017)... Scottsdale, AZ (PRWEB) , ... September 22, 2017 ... ... announced that it recently raised nearly $200,000 via Kickstarter. The proceeds will be ... 623 backers pre-ordered the B2v2, exceeding the original Kickstarter goal by nearly 1,000%. ...
Breaking Biology Technology:
(Date:8/23/2017)... ARMONK, N.Y. , Aug. 23, 2017  The general public,s help ... the human microbiome—the bacteria that live in and on the human body ... ... bacteria in the human microbiome, starting with the gut. The project's goal ... in disease. Photo credit: IBM ...
(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a ... intravenous (IV) therapy, today announced receipt of its ISO 13485 Certification, ... by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early ... "This is an ...
(Date:7/20/2017)... WASHINGTON , July 20, 2017 Delta (NYSE: ... to board any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics ... Delta,s ... Delta Sky Club is now integrated into the boarding process to ...
Breaking Biology News(10 mins):